In an open-label study, researchers determined whether platelet function monitoring-guided adjustment of antiplatelet therapy benefitted patients with UIA with stent placement compared with those who received standard DAPT without platelet function monitoring.
In a large-scale analysis, researchers determined whether endovascular mechanical thrombectomy is a safe and effective therapy for acute ischemic stroke during pregnancy and the postpartum period.
Coffee and tea consumption separately and in combination are associated with a reduced risk for developing stroke and dementia.
Endovascular treatment alone is neither superior nor noninferior to intravenous alteplase followed by EVT in a cohort of European patients with stroke.
Researchers at AHA 2021 presented their findings on a study that examined how vegetable, dairy, and nondairy fats can affect stroke risk.
Researchers at AHA 2021 presented their findings from a study that compared CVD risk factors and in-hospital outcomes in young, Black US adults a decade apart.
Researchers at AHA 2021 presented a study on the effects of e-cigarettes among people with a history of stroke.
For smokers who survive a stroke, the overall quit ratio is 60.8 percent, with stroke survivors less likely to quit smoking than cancer survivors.
In an observational study, researchers assessed outcomes from mobile stroke units or emergency medical services within 4.5 hours after onset of acute stroke symptoms.
![Decisions regarding thromboprophylaxis requires weighing the risk of stroke against the risk of bleeding in each patient.[3,4] Numerous risk assessment tools are available, including CHADS2, CHA2DS2-VASc, and HAS-BLED. American and European guidelines recommend the use of CHA2DS2-VASc, which considers sex, age, and history of congestive HF, hypertension, stroke/transient ischemic attack/thromboembolism, vascular disease, and diabetes mellitus.[3,4] Compared with other stroke risk assessment measures, this tool performed best in identifying patients at low risk of stroke who did not require anticoagulation therapy.[12] Oral anticoagulation is recommended in any patient with a score ≥2 on the CHA2DS2-VASc. In these patients, warfarin or the novel anticoagulants dabigatran, rivaroxaban, apixaban, or edoxaban can be considered, except in the setting of moderate to severe chronic kidney disease, where reduced doses of direct thrombin or factor Xa inhibitors are preferable.[4]](https://www.neurologyadvisor.com/wp-content/uploads/sites/10/2021/11/slideshowsizeatrialfibrillati_1061315-544x306.jpg)
Researchers examined the 4-year outcomes of the PRAGUE-17 trial, which compared the effectiveness of LAA closure against NOACs for preventing cardioembolic events in AF.
